Erratum: Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort (Eur Respir J (2015) 46 (1308–1321) DOI: 10.1183/13993003.00779-2015);Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort

European Respiratory Journal

Volumn 46, Issue 5, 2015, Pages 1308-1321

  Shaw, Dominick E ^a   Sousa, Ana R ^b   Fowler, Stephen J ^c   Fleming, Louise J ^d   Roberts, Graham ^e,f,g   Corfield, Julie ^h,i   Pandis, Ioannis ^j   Bansal, Aruna T ^k   Bel, Elisabeth H ^l   Auffray, Charles ^m   Compton, Chris H ^b   Bisgaard, Hans ⁿ   Bucchioni, Enrica ^o   Caruso, Massimo ^p   Chanez, Pascal ^q   Dahlén, Barbro ^r   Dahlen, Sven Erik ^s   Dyson, Kerry ^t   Frey, Urs ^u   Geiser, Thomas ^v   De Verdier, Maria Gerhardsson ^h   Gibeon, David ^d   Guo, Yi Ke ^j   Hashimoto, Simone ^a,b   Hedlin, Gunilla ^s   Jeyasingham, Elizabeth ^b   Hekking, Pieter Paul W ^l   Higenbottam, Tim ^w   Horváth, Ildikó ^x   Knox, Alan J ^a   Krug, Norbert ^y   Erpenbeck, Veit J ^z   Larsson, Lars X ^h   Lazarinis, Nikos ^r   Matthews, John G ^aa   Middelveld, Roelinde ^t   Montuschi, Paolo ^ab   Musial, Jacek ^ac   Myles, David ^b   Pahus, Laurie ^ad   Sandström, Thomas ^ae   Seibold, Wolfgang ^af   Singer, Florian ^ag   Strandberg, Karin ^r   Vestbo, Jorgen ^ah   Vissing, Nadja ^ai   Von Garnier, Christophe ^v,aj   Adcock, Ian M ^d,ak   Wagers, Scott ^al   Rowe, Anthony ^am   Howarth, Peter ^f   Wagener, Ariane H ^l   Djukanovic, Ratko ^f   Sterk, Peter J ^l   Chung, Kian Fan ^d,ak   more..

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e University Hospital Southampton NHS Foundation Trust   (United Kingdom)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g ST MARY S HOSPITAL   (United Kingdom)

^h ASTRAZENECA R AND D   (Sweden)

ⁱ Areteva R and D   (United Kingdom)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

^k Acclarogen Ltd   (United Kingdom)

^l UNIVERSITY OF AMSTERDAM   (Netherlands)

^m UNIVERSITÉ DE LYON   (France)

ⁿ UNIVERSITY OF COPENHAGEN   (Denmark)

^o CHIESI FARMACEUTICI S P A   (Italy)

^p UNIVERSITY OF CATANIA   (Italy)

^q AIX MARSEILLE UNIVERSITY   (France)

^r KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^s KAROLINSKA INSTITUTE   (Sweden)

^t CROMSOURCE   (United Kingdom)

^u UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^v UNIVERSITY OF BERN   (Switzerland)

^w Allergy Therapeutics plc   (United Kingdom)

^x SEMMELWEIS UNIVERSITY   (Hungary)

^y FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^z NOVARTIS PHARMA AG   (Switzerland)

^aa GENENTECH INC   (United States)

^ab CATHOLIC UNIVERSITY   (Italy)

^ac JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^ad HÔPITAL NORD   (France)

^ae UMEÅ UNIVERSITY   (Sweden)

^af BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^ag UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^ah UNIVERSITY OF MANCHESTER   (United Kingdom)

^ai UNIVERSITY OF COPENHAGEN   (Denmark)

^aj Spital Bern Tiefenau   (Switzerland)

^ak ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^al BIOSCI CONSULTING   (Belgium)

^am JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE; METHACHOLINE; PREDNISOLONE; SALBUTAMOL; ANTIASTHMATIC AGENT; CORTICOSTEROID; NITRIC OXIDE;

ADULT; ANXIETY DISORDER; ASTHMA; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; CONFERENCE PAPER; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG INDUSTRY; DRUG MEGADOSE; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GASTROESOPHAGEAL REFLUX; HEALTH CARE ORGANIZATION; HUMAN; INCIDENCE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE POLYP; OUTCOME ASSESSMENT; PATIENT CARE; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RESPIRATORY TRACT INFLAMMATION; SPIROMETRY; ADVERSE EFFECTS; ANXIETY; CASE CONTROL STUDY; COMPLICATION; EUROPE; MIDDLE AGED; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; SMOKING; SYSTEMS BIOLOGY;

ADRENAL CORTEX HORMONES; ADULT; ANTI-ASTHMATIC AGENTS; ANXIETY; ASTHMA; CASE-CONTROL STUDIES; COMORBIDITY; CROSS-SECTIONAL STUDIES; DEPRESSION; EUROPE; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; PROSPECTIVE STUDIES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SMOKING; SPIROMETRY; SURVEYS AND QUESTIONNAIRES; SYSTEMS BIOLOGY;

EID: 84946599963     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.50779-2015     Document Type: Erratum

References (34)

1. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343-373.
2. Bel EH, Sousa A, Fleming L, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011; 66: 910-917.
3. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651-659.
4. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368: 2455-2466.
5. Wu W, Bleecker E, Moore W, et al. Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. J Allergy Clin Immunol 2014; 133: 1280-1288.
6. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218-224.
7. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18: 716-725.
8. Wheelock CE, Goss VM, Balgoma D, et al. Application of 'omics technologies to biomarker discovery in inflammatory lung diseases. Eur Respir J 2013; 42: 802-825.
9. Auffray C, Adcock IM, Chung KF, et al. An integrative systems biology approach to understanding pulmonary diseases. Chest 2010; 137: 1410-1416.
10. Bousquet J. Global initiative for asthma (GINA) and its objectives. Clin Exp Allergy 2000; 30: Suppl. 1, 2-5.
11. Pavord ID, Pizzichini MM, Pizzichini E, et al. The use of induced sputum to investigate airway inflammation. Thorax 1997; 52: 498-501.
12. Szalma S, Koka V, Khasanova T, et al. Effective knowledge management in translational medicine. J Transl Med 2010; 8: 68.
13. Juniper EF, O'Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14: 902-907.
14. Juniper EF, Guyatt GH, Ferrie PJ, et al. Measuring quality of life in asthma. Am Rev Respir Dis 1993; 147: 832-838.
15. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370.
16. Morley AD, Sharp HR. A review of sinonasal outcome scoring systems-which is best? Clin Otolaryngol 2006; 31: 103-109.
17. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-545.
18. Cohen JL, Mann DM, Wisnivesky JP, et al. Assessing the validity of self-reported medication adherence among inner-city asthmatic adults: the Medication Adherence Report Scale for Asthma. Ann Allergy Asthma Immunol 2009; 103: 325-331.
19. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003; 22: 470-477.
20. Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119: 405-413.
21. Schleich FN, Manise M, Sele J, et al. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med 2013; 13: 11.
22. Chaudhuri R, Livingston E, McMahon AD, et al. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003; 168: 1308-1311.
23. Silva GE, Sherrill DL, Guerra S, et al. Asthma as a risk factor for COPD in a longitudinal study. Chest 2004; 126: 59-65.
24. Bleecker ER. Similarities and differences in asthma and COPD. The Dutch hypothesis. Chest 2004; 126: Suppl., 93S-95S.
25. Galli J, Montuschi P, Passàli GC, et al. Exhaled nitric oxide measurement in patients affected by nasal polyposis. Otolaryngol Head Neck Surg 2012; 147: 351-356.
26. Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013; 131: 110-116.
27. Heaney LG, Brightling CE, Menzies-Gow A, et al. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. Thorax 2010; 65: 787-794.
28. Schleich F, Brusselle G, Louis R, et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med 2014; 108: 1723-1732.
29. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59-99.
30. McGrath KW, Icitovic N, Boushey HA, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012; 185: 612-619.
31. Jatakanon A, Uasuf C, Maziak W, et al. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999; 160: 1532-1539.
32. Moore WC, Hastie AT, Li X, et al. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol 2014; 133: 1557-1563.
33. Dixon AE, Pratley RE, Forgione PM, et al. Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J Allergy Clin Immunol 2011; 128: 508-515.
34. Arterburn DE, Olsen MK, Smith VA, et al. Association between bariatric surgery and long-term survival. JAMA 2015; 313: 62-70.